Jazz Pharmaceuticals and AbCellera Collaborate on Antibody Programs for Solid Tumors

Jazz Pharmaceuticals (NASDAQ: JAZZ) has partnered with AbCellera (NASDAQ: ABCL) to develop multispecific antibodies targeting solid tumors, particularly gastrointestinal cancers. The collaboration includes upfront payments of up to $84 million and potential future milestone fees exceeding $792 million per program if development options are exercised.

By Fiona Craig Wed, June 17, 2026 at 3:50 PM GMT+3 2 min read · Yahoo Finance · June 17, 2026, 12:50 UTC

Tickers: $JAZZ

Topics: antibody development cancer research pharmaceuticals

Read the full article at Yahoo Finance

More World news

Canadian Tire Announces Quarterly Dividend of CAD 1.825 Per Share Seeking Alpha · November 12, 2026, 13:58 UTC
Chicago Atlantic BDC Announces $0.34 Per Share Quarterly Dividend Seeking Alpha · November 12, 2026, 13:59 UTC
William Blair Upgrades AMD to Outperform Amid Leadership Crisis at Nvidia CNBC · November 12, 2026, 13:56 UTC
HawkEye 360 Secures $135 Million in New Global Contracts Seeking Alpha · November 12, 2026, 13:55 UTC
Databento Secures $100 Million Series C Funding at $1.1 Billion Valuation PR Newswire · November 12, 2026, 13:57 UTC
Annex Brands Announces Franchise Renewal for Postal Connections in Fort Mohave, Arizona PR Newswire · November 12, 2026, 13:58 UTC
Nvidia CEO Jensen Huang Resigns Following Personal Scandals and Espionage Allegations The Verge · November 12, 2026, 13:53 UTC
AMD and PsiQuantum Partner to Develop Fault-Tolerant Quantum Computing Infrastructure Seeking Alpha · November 12, 2026, 13:44 UTC
Nvidia CEO Jensen Huang Resigns; CFO Colette Kress Appointed Interim CEO Seeking Alpha · November 12, 2026, 13:50 UTC
Aktis Oncology Reports Q3 Revenue Growth and Significant Increase in Cash Reserves Seeking Alpha · November 12, 2026, 13:50 UTC